CFTR and cystic fibrosis: An investigational CFTR potentiator proposed by Proteostasis Therapeutics—PTI-808—was found to enhance the function of F508del-CFTR (2018 ECFS Conference, New Frontiers in Basic Science of Cystic Fibrosis) and is currently in Phase I clinical trials together with PTI-801 and PTI-428 as a combination therapy.